508 related articles for article (PubMed ID: 17682127)
1. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
Fujino M; Funeshima N; Kitazawa Y; Kimura H; Amemiya H; Suzuki S; Li XK
J Pharmacol Exp Ther; 2003 Apr; 305(1):70-7. PubMed ID: 12649354
[TBL] [Abstract][Full Text] [Related]
5. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K
Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494
[TBL] [Abstract][Full Text] [Related]
6. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
7. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.
Balatoni B; Storch MK; Swoboda EM; Schönborn V; Koziel A; Lambrou GN; Hiestand PC; Weissert R; Foster CA
Brain Res Bull; 2007 Oct; 74(5):307-16. PubMed ID: 17845905
[TBL] [Abstract][Full Text] [Related]
8. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
10. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
Papadopoulos D; Rundle J; Patel R; Marshall I; Stretton J; Eaton R; Richardson JC; Gonzalez MI; Philpott KL; Reynolds R
J Neurosci Res; 2010 Feb; 88(2):346-59. PubMed ID: 19658199
[TBL] [Abstract][Full Text] [Related]
11. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
12. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
[TBL] [Abstract][Full Text] [Related]
13. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors.
Coelho RP; Payne SG; Bittman R; Spiegel S; Sato-Bigbee C
J Pharmacol Exp Ther; 2007 Nov; 323(2):626-35. PubMed ID: 17726159
[TBL] [Abstract][Full Text] [Related]
14. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
15. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
16. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
Foster CA; Mechtcheriakova D; Storch MK; Balatoni B; Howard LM; Bornancin F; Wlachos A; Sobanov J; Kinnunen A; Baumruker T
Brain Pathol; 2009 Apr; 19(2):254-66. PubMed ID: 18540945
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
[TBL] [Abstract][Full Text] [Related]
18. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
20. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves.
Zhang Z; Zhang ZY; Fauser U; Schluesener HJ
Exp Neurol; 2008 Apr; 210(2):681-90. PubMed ID: 18261728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]